Scil Proteins strengthens oncology activities with R&D collaborations
This article was originally published in Scrip
Executive Summary
Scil Proteins has signed a collaboration agreement with the Martin Luther University Halle-Wittenberg in Germany to research therapies for gastrointestinal tumours. Separately, the company told Scrip that it also has an ongoing "industrial cooperation" for its oncology programme and is currently in the process of setting up other such collaborations.